Mediastinal staging in non-small-cell lung cancer (NSCLC) is crucial for correct prognosis and therapeutic choices. When no distal metastases are present, mediastinal involvement is the most important prognostic factor; 1 therefore, mediastinal exploration represents an important resource-consuming step in patient evaluation. Some of these techniques -PET, mediastinoscopy and EUS-FNAprovide very sensitive and specific results. TBNA alone, on the other hand, although highly specific, has not proved to be sufficiently sensitive and may provide false-negative results; its performance improves when supported by EBUS.
node enlargement, although a high interobserver variability rate may exist. 2 The literature reports good specificity of CT (about 80%) and moderate sensitivity (not above 60%). 3 This may imply that an enlarged mediastinal lymph node (short axis ≥1cm) in a patient affected by lung cancer may in fact be healthy in four cases out of 10, whereas metastasis may be found in up to 20% of patients with normal size lymph nodes (short axis <1cm). Therefore, secondary neoplastic localisation cannot be diagnosed uniquely on the basis of the dimensions of the lymph nodes, 4 and CT thus plays a central role in guiding the choice of the most appropriate procedure for node biopsy.
Accordingly, the recent American College of Chest Physicians (ACCP) guidelines on mediastinal staging report that CT may be considered sufficient only in cases of massive mediastinal invasion; in any other cases, further diagnostic techniques should be implemented. 5 
Positron-emission Tomography
PET is probably the most revolutionary diagnostic technique of the last 20 years in the investigation of NSCLC. [6] [7] [8] [9] Its sensitivity and specificity are 75-91% and 78-93%, respectively, depending on lymph node size. 10 Its overall sensitivity and negative predictive value are comparable to those of mediastinoscopy, such that mediastinal negativity on PET paves the way to the use of surgery with no need for further examinations. [10] [11] [12] [13] [14] However, despite a small amount of reported false-negatives (5-8%), a recent meta-analysis showed that in patients with normal-sized lymph nodes the false-negative rate may reach 25%. 15 This happens above all for central 5, 16, 17 or large tumours 1, 18 or for tumours with an elevated standardised uptake value (SUV). 18, 19 Nevertheless, owing to its high performance, PET is considered the reference test for all potentially operable patients. 20 
Needle Aspiration Techniques
The use of TBNA in lung cancer staging has recently been steadily increasing. The sensitivity and specificity of this technique are around 76 and 98%, respectively. 21 When rapid on-site examination (ROSE) is coupled with TBNA, 22 the performance of TBNA increases owing to the shorter duration and lesser risks of the procedure according to some authors, 23 or because of better accuracy according to others. 24, 25 When supported by other complementary techniques, such as EBUS, TBNA yield may improve, and its sensitivity may rise >90% when a convex probe is used, which allows direct observation of the needle piercing the lymph node. [26] [27] [28] [29] However, in clinical practice the worthwhile application of ultrasound appears limited to lymph nodes at American Thoracic Society (ATS) stations one and two (in such cases endoscopists have no definite safe landmarks for the puncture), to small lymph nodes (≤5mm) and when ROSE is not performed. 30, 31 Similar to TBNA, EUS-FNA provides high sensitivity and specificity; its major limitations are lymph nodes anterior to the trachea and to the main bronchi. [32] [33] [34] As for other needle aspiration techniques, a positive result can be considered definitive for staging, while surgical confirmation is generally required in the event of a negative result. Lung Cancer believe that CT and PET negativity on the mediastinum allows biopsy and surgery to be avoided, except in cases of T3 or adenocarcinoma, where mediastinal metastasis gives a poor prognosis. In addition, one must keep in mind that PET alone cannot easily distinguish between the central tumour and mediastinal metastasis.
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New Developments
Many of the mediastinal approaches discussed above take into account to some degree of the a priori probability that a given tumour will produce mediastinal metastasis, thus identifying different situations in which the same test can be conclusive for a surgical decision or, conversely, where the probability of occult mediastinal metastasis remains high even in the case of a negative result.
Moreover, there is general agreement that a negative cytological result must always be confirmed surgically. However, only a few works have looked for objective criteria to distinguish a negative from an inadequate sample and have suggested different evaluation methods in the two cases. 36, 37 No work, to our knowledge, has ever tried to integrate the performance of all diagnostic tests and negative prognostic factors to build up one synthetic model in which the evaluation of negative results (including negative cytological results) is not absolute, but is related to pre-test data and therefore to the The Challenge of Mediastinal Staging 73 we suggested a mathematical model using Bayes' theorem that enables the probability of nodal metastasis to be predicted after a certain number of diagnostic procedures has been performed, providing a simple way of evaluating when a patient can undergo surgery or, conversely, whether further investigations are required. Figure 1 shows a flowchart focusing on a reasoned study of mediastinum using probability calculations. Surgery is considered a possible choice whenever the probability of mediastinal metastasis falls below 10%.
Figure 2: Simplified Algorithm for Mediastinal Study
Endobronchial ultrasound/endoscopic ultrasound-guided (EBUS/EUS) if tumour (T) standardised uptake value (SUV) >10; patient's age <65 years; right upper lobe of lung (RUL
For example (see Figure 2) , in peripheral T1, a CT-negative mediastinum indicates a <10% probability of metastasis; in this case, immediate resort to surgery may be considered reasonable. Positive CT indicates a probability of metastasis of up to about 40%; in this case, negative PET would authorise surgery (1-7% probability of mediastinal metastasis).
Conversely, in clinical stage 2 (pre-test probability of mediastinal metastasis 40-60%), negative PET would not exclude with a sufficient safety margin the presence of mediastinal metastasis (probability 12-17%). Cytological study of the mediastinum must therefore be performed regardless of the PET result. Furthermore, if PET is positive, a negative cytology would not be sufficient and mediastinoscopy will be mandatory. As in any mathematical product, no matter which test (PET or TBNA) is performed first, the result will be the same.
We can therefore identify three main clinical-radiological phenotypes in NSCLC (see Figure 3 ):
• Phenotype a: The probability of mediastinal metastasis is <20%.
In this case, negativity on either CT or PET authorises surgery.
• Phenotype b: The probability of mediastinal metastasis is about 30-40%. In this case, surgery may be suggested when both CT and PET are negative.
• Phenotype c: The probability of mediastinal metastasis is >40%. In this case, surgery is indicated only when both PET and cytology are negative. In any other case, surgical confirmation is necessary.
Conclusions
Mediastinal staging is crucial to ensure the best therapeutic option is 
